Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | colorectal cancer | sensitive | Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (BREAKWATER) that supported FDA approval, Braftovi (encorafenib) in combination with Erbitux (cetuximab) and mFOLFOX6 (n=27) or FOLFIRI (n=30) were tolerated and resulted in a median duration of treatment of 14 and 15 weeks, respectively, in patients with metastatic colorectal cancer harboring BRAF V600E, with treatment ongoing in 79% (45/57) of the patients at data cutoff date (J Clin Oncol Vol 40, Number 4 Suppl (Feb 2022); NCT04607421). | detail... detail... detail... detail... |
BRAF V600E | colorectal cancer | sensitive | Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with the combination of Erbitux (cetuximab), Braftovi (encorafenib), and FOLFOX resulted in increased tumor growth inhibition and survival compared to Erbitux (cetuximab) plus Braftovi (encorafenib) or FOLFOX alone in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 37040395). | 37040395 |
PubMed Id | Reference Title | Details |
---|---|---|
Full reference... | ||
Braftovi (encorafenib) FDA Drug Label | Full reference... | |
Erbitux (cetuximab) FDA Drug Label | Full reference... | |
(37040395) | Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer. | Full reference... |
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). | Full reference... |